

**AMENDMENTS TO CLAIMS (Clean copy)**

**WHAT IS CLAIMED IS:**

1. (Currently amended) An isolated, purified peptide, consisting essentially of a tripeptide of amino acid sequence L- Tyrosyl-L-Seryl-L-Valine.
2. Canceled
3. (Currently amended) A pharmaceutical composition, comprising a purified, isolated tripeptide of amino acid sequence L-Tyrosyl-L-Seryl-L-Valine; and a pharmaceutically or biologically acceptable carrier.
4. (Currently amended) A method of reducing, countering or inhibiting T-lymphocyte transformation or cell proliferation, or a disease or condition associated with it, comprising administering to a subject in need of treatment a therapeutically effective amount of a tripeptide of amino acid sequence Tyrosyl-Seryl-Valine.
5. (Currently amended) The method of claim 4, wherein the disease or condition is associated with, or comprises a cancer.
6. (Currently amended) The method of claim 4, wherein the disease or condition is associated with, or comprises liver cancer, leukemia, lung cancer, melanoma or cervical cancer.
7. (Canceled)
8. (Canceled)
9. (New) The peptide of claim 1, which comprises a substantially pure tripeptide.
10. (New) The method of claim 4, wherein the therapeutically effective amount of the tripeptide comprises an anti-T-cell transformation, anti-cell proliferation, or anti-cancer effective amount of the tripeptide.
11. (New) The method of claim 4, wherein the therapeutically effective amount of the tripeptide comprises a liver cancer, leukemia cell, cervical cancer, lung cancer or melanoma growth countering, reducing or inhibiting amount of the tripeptide.
12. (New) The method of claim 4, wherein the tripeptide is administered as a pharmaceutical composition further comprising a pharmaceutically or biologically acceptable carrier.